Publication | Closed Access
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
179
Citations
14
References
2021
Year
| Year | Citations | |
|---|---|---|
Page 1
Page 1